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Background: The three primary headaches, tension-type headache, migraine and cluster headache, occur in both
genders, but all seem to have a sex-specific prevalence. These gender differences suggest that both male and
female sex hormones could have an influence on the course of primary headaches. This review aims to summarise
the most relevant and recent literature on this topic.
Methods: Two independent reviewers searched PUBMED in a systematic manner. Search strings were composed using
the terms LH, FSH, progesteron*, estrogen*, DHEA*, prolactin, testosterone, androgen*, headach*, migrain*, “tension type”
or cluster. A timeframe was set limiting the search to articles published in the last 20 years, after January 1st 1997.
Results: Migraine tends to follow a classic temporal pattern throughout a woman’s life corresponding to the fluctuation
of estrogen in the different reproductive stages. The estrogen withdrawal hypothesis forms the basis for most of the
assumptions made on this behalf. The role of other hormones as well as the importance of sex hormones in other
primary headaches is far less studied.
Conclusion: The available literature mainly covers the role of sex hormones in migraine in women. Detailed studies
especially in the elderly of both sexes and in cluster headache and tension-type headache are warranted to fully elucidate
the role of these hormones in all primary headaches.
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GenderIntroduction
The primary headaches covered in this review are
tension-type headache (TTH), migraine and cluster
headache (CH). All three entities occur in both men and
women, yet display a sex-specific prevalence. These gen-
der differences suggest that both male and female sex
hormones could have an influence on the course of pri-
mary headaches.
TTH has a female preponderance, and is 1.5 times
more frequent in women than in men [1]. CH, on the
other hand, appears to have a higher incidence in men,
specifically during young adulthood and middle age.
Later in life the prevalence of CH evens out between the* Correspondence: zoe.delaruelle@uzgent.be
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role of sex hormones has been studied most profoundly
in migraine. Prepubertal children have a 3-10% preva-
lence of migraine without any gender difference [3, 4].
With onset of puberty and its associated hormonal
changes, migraine becomes 2–3 times more common in
women than in men, suggesting that migraine is influ-
enced by the fluctuating hormonal status through me-
narche, menstruation, pregnancy, menopause, as well as
the use of oral contraceptives and hormonal replacement
therapy (HRT) [1, 3, 5–8].
In contrast, the course of migraine throughout the life-
span of men appears relatively stable, further pointing to
the unique role of female sex hormones in the migraine
phenotype [1]. Here, we summarise relevant literature of
the last 20 years covering the influence of female and
male sex hormones on primary headaches.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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Two independent reviewers conducted a search on
PubMed, using their own search string, composed of
terms like LH, FSH, Progesteron*, estrogen*, DHEA*, Pro-
lactin, Testosterone, androgen*AND Headach* OR
Migrain* OR “Tension type” OR Cluster. This general
search was performed on December 7th, 2017. In light of
the large amount of published work on the topic and con-
sidering the evolution of the diagnostic criteria over time,
the first search was conducted respecting a timeframe of
20 years, covering articles published after January 1st
1997. The initial screening was performed based on eligi-
bility of title and abstract. Exclusion criteria included
non-availability of abstract, animal studies, and articles in
any language other than English. Original studies, pub-
lished in full, constitute the core of this review. Other
quoted references include systematic reviews, case reports,
meta-analysis, Cochrane reviews, letters, lectures and
comments. Any relevant publications cited in the eligible
articles were also included. Differences between reviewers
were resolved by careful discussion.
Results
Women
Childhood and adolescence
Almost 60% of girls and 50% of boys suffer from head-
ache at some time during childhood and adolescence,
with the prevalence increasing significantly during ado-
lescence in girls, whereas it remains stable for boys [9].
The incidence of migraine is similar in both sexes until
the age of 9 (2.5% of girls and 2.4% of boys) and then di-
verges to the disadvantage of girls [6]. Teenagers who
suffer from headache are at greater risk of having head-
ache in adulthood [9].
It is known that during puberty, sexual steroid hor-
mones affect neural circuits and cause permanent
changes in important brain areas such as the hypothal-
amus and the insula [4]. Onset of migraine frequently
occurs around the time of menarche, as cyclic hormonal
changes begin. Early menarche appears to be a risk fac-
tor for the development of migraine [6, 10]. Notably, the
first menstrual cycles are often anovulatory and in gen-
eral ovulation occurs one or two years later. In the USA,
the average age of menarche is 12.8 years, but this may
vary geographically. Migraine with aura has an incidence
peak between ages 12 to 13, while migraine without aura
typically presents a few years later. Thus, migraine with-
out aura may be associated with the establishment of a
regular ovulatory menstrual cycle [7]. Headaches are re-
ported in 53% of adolescent girls at the onset of menses.
Pubertal development and age seem to modulate the ef-
fect of ovarian hormones on migraine. In fact, high urin-
ary levels of pregnandiol glucuronide, a metabolite of
progesterone, are associated with a higher migrainefrequency in girls before menarche, but with a lower fre-
quency after menarche [11]. Hershey et al. identified spe-
cific genomic patterns in girls suffering from menstrual
migraine, suggesting a genetic predisposition for the de-
velopment of this condition during adolescence [12].
TTH shows a similar, increasing trend in girls by the
time of menarche. The incidence ratio between boys and
girls changes from 1.3:1 during childhood to 1:1.2 after
menarche [13].
It is noteworthy to mention, that pathological changes in
sexual hormones can cause a secondary headache. For in-
stance, hyperprolactinemia manifests in up to 45% of child-
hood cases with headache as a first symptom [14–16].
Adulthood
Migraine Women have a 3.25-fold higher risk of suffer-
ing from migraine than men [17]. A prevalence peak is
reached in women between the ages of 35 and 45, with
25-30% of the general female population being affected,
in comparison to only 8% of the general male population
[18]. Female migraine patients also report a significant
higher burden of disease and greater use of analgesic
compared to men [6, 13].
In terms of deciphering the pathophysiological mech-
anism of the preponderance of migraine in women, neu-
roimaging studies have revealed sex-specific activation
patterns, with an increased activation of the insula and
precuneus in women. These regions are involved in pain,
sensation and affective processing [19]. Sex hormones
can cross the blood-brain barrier passively and are at
least partially responsible for these sex differences [18].
Most available literature focuses on the effects of estro-
gen, while the role of progesterone has been less thor-
oughly investigated.
The relationship between estrogen and migraine is
complex, involving modulation by genomic and
non-genomic effects [20, 21]. Obese women appear to
have more than a twofold risk of episodic and chronic
migraine, probably due to the pathological estrogen pro-
duction in adipose tissue [22, 23]. Substantial evidence
points to the serotonergic system as a key player in mi-
graine pathogenesis [7]. Estrogen modulates serotonergic
neurotransmission, by increasing the expression of the
tryptophan hydroxylase and decreasing the expression of
the serotonin reuptake transporter [7, 24, 25]. Estrogen
also activates the endogenous opioidergic system, which
has an analgesic effect on persistent, inflammatory pain
[26]. Furthermore, estrogen induces vascular changes by
modulating vasodilation and suppressing vascular in-
flammatory responses [6, 27, 28].
The levels of calcitonin gene-related peptide (CGRP), a
neuropeptide with a key role in migraine pathophysi-
ology, are higher in women of reproductive age than in
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lease and consequently the trigeminovascular system
[29]. While studies have reported a positive relationship
between CGRP and estrogen levels, newer studies sug-
gest an inverse relationship between the two [24].
Experimental studies suggest progesterone to play a
protective role, by reducing nociception in the trigemi-
novascular system, inhibiting neurogenic edema, and
histamine secretion from mast cells and decreasing pros-
taglandin production [7, 24, 30, 31].
Multiple studies have examined the association be-
tween polymorphisms in estrogen or progesterone re-
ceptor genes and migraine risk, with inconclusive
findings [32–37]. In their meta-analysis, Schürks et al.
and Li et al. concluded that exon 4 325C > G and exon 8
594G > A polymorphisms are risk factors for migraine,
while the often examined PROGINS variant in the pro-
gesterone receptor gene did not seem to play a signifi-
cant role in the Caucasian population [38, 39]. On the
contrary, Joshi et al. found a protective role of the PRO-
GINS polymorphism in an Indian population [40].
Prolactin could also play a modulatory role in mi-
graine. Parashar et al. found higher prolactin levels in
migraineurs compared to controls [41]. An association
between high prolactin levels and migraine chronifica-
tion has been proposed by Cavestro et al. [42], where
Peres et al. detected decreased nocturnal prolactin peaks
in chronic migraine patients [43].
There are a few reports suggesting that testosterone
can play a role in migraine in women [44, 45]. In one
case report, the 5α reductase inhibitor finasteride was
administered to a young woman with migraine and led
to an almost complete remission [45]. The mechanism
of action of testosterone on migraine pathophysiology is
still unknown, but may involve modulation of cerebral
blood flow, serotonergic tone, and susceptibility to cor-
tical spreading depression [44].
Menstrual migraine The probability of migraine to
occur during the perimenstrual period is twice as high
compared to any other moment of the menstrual cycle
[46]. Almost half of female migraine patients report an
association between headache and their menstrual cycle
[17]. Depending on whether migraine occurs exclusivelyTable 1 IHS classification (ICHD-3) for pure menstrual and menstrua
Pure menstrual migraine
A. Attacks, in a menstruating woman, fulfilling criteria for migraine
without aura
B. Attacks occur exclusively on day 1 ± 2 (i.e, days − 2 to + 3)a of
menstruationb in at least two out of three menstrual cycles and at
no other times of the cycle
aThe first day of menstruation is day 1 and the preceding day is day − 1; there is no
bFor the purposes of this classification, menstruation is considered to be endometri
withdrawal of exogenous progestogens, as in the case of combined oral contraceptduring the perimenstrual period or also at other times,
the International Headache Society (IHS) distinguishes a
pure menstrual migraine from a menstrually-related mi-
graine (Table 1). Migraine associated with menstruation
is mostly of the type without aura [21].
Pure menstrual migraine and menstrually-related mi-
graine have an overall prevalence of respectively 1% and
7% in the general population [47]. Data from specialized
headache clinics suggest that perimenstrual attacks are
more severe, long-lasting and difficult to treat with
abortive anti-migraine medication [48]. However, these
results could not be confirmed in the general population
[49]. Menstrual migraine appears to limit work and so-
cial activities more frequently than common migraine
and is often associated with a dysphoric mood [17].
The “Estrogen withdrawal hypothesis”, developed by
Somerville and colleagues in 1972, postulates that at-
tacks of menstrual migraine are triggered by the de-
crease in estrogen levels preceding menstruation [21]. A
drop in estrogen may cause an increased sensitivity to
prostaglandins and a release of neuropeptides such as
CGRP, substance P and neurokinins which could result
in neurogenic inflammation [17]. This physiological re-
sponse provokes alterations in the microvasculature of
the dura mater, changes in calcium and magnesium con-
centrations, and an imbalance in serotonin and dopa-
mine concentrations [17, 21, 50]. Estrogen withdrawal
might lead to an increased oxidative stress in the cells
[51]. To confirm this hypothesis, intramuscular injec-
tions of estrogen were administered before menstruation
and thereby postponing migraine attacks [52, 53]. On
the contrary, progesterone injections only led to post-
pone menses, but not migraine [52, 54].
More recent studies confirm that an estrogen drop
can trigger migraine, especially if this drop is preceded
by a phase of high estrogen levels, as in the luteal phase
of the menstrual cycle, and if the magnitude of the de-
crease is greater than 10 μg [55, 56]. Interestingly,
women with migraine seem to have a faster drop in es-
trogen levels than non-migraineurs [57].
Welch et al. tried to explain estrogen effects on men-
strual migraine with a “mismatch theory”. Under normal
circumstances, genomic effects of estrogen can counter-
balance non-genomic mediated membrane excitability.lly-related migraine
Menstrually-related migraine
A. Attacks, in a menstruating woman, fulfilling criteria for migraine
without aura
B. Attacks occur on day 1 ± 2 (i.e, days − 2 to + 3)a of menstruationb in
at least two out of three menstrual cycles and additionally at other times
of the cycle
day 0
al bleeding resulting from either the normal menstrual cycle or from the
ives and cyclical hormone replacement therapy
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does not suffice, and migraine attacks occur more fre-
quently [58, 59].
In one retrospective study with 85 female patients with
menstrual migraine, 35.3% reported migraine headache
onset by the end of menstruation, which is days after the
estrogen drop. The authors hypothesize that this type of
migraine headache is not related to hormonal changes but
most probably to transient anemia due to blood loss [56].
Hormonal treatment of menstrual migraine, like peri-
menstrual application of estrogen gel or a transdermal
estradiol patch, can lead to less frequent, shorter and
less intensive attacks [46, 47, 52, 60]. Attacks may recur
after discontinuation of hormonal treatment [17]. Fol-
lowing the estrogen withdrawal hypothesis, eliminating
estrogen cycling appears to be a useful strategy for
long-term prophylaxis of menstrual migraine. Therefore,
continuous combined contraceptive therapy regimes,
containing both estrogen and progesterone, can be con-
sidered. However, there is currently no evidence that
hormonal therapy is more effective than non-hormonal
pharmacological treatment strategies. Hormonal therapy
is particularly recommended if other indications like
acne or hirsutism exist. Contraindications should be
ruled out [17, 53]. Alternatively, progesterone-only con-
traceptives can be considered. A significant reduction in
migraine intensity and frequency is reported [17, 61–63].
As progesterone has no experimental effect on cortical
spreading depression, progesterone-only contraception is
hypothesized to be a safer choice for women with aura
[62, 64], but no clinical evidence has confirmed this the-
ory. The selective estrogen receptor modulator Tamoxi-
fen might also be beneficial in women with menstrual
migraine. However, its use is not generally recom-
mended due to possible and in part serious side effects
[65]. Some studies suggest that phytoestrogens like soy
isoflavone, dong quai or black cohosh could have a
beneficial effect on migraine [17]. Martin et al. examined
the efficacy of the gonadotropin-releasing hormone an-
tagonist goserelin as a prophylactic therapy. Goserelin
alone did not affect migraine headache frequency. Some
benefit was obtained when combined with 100 μg estra-
diol [66]. Glaser et al. demonstrated that continuous tes-
tosterone therapy through a subcutaneous implant forTable 2 IHS classification (ICHD-3) for exogenous hormone-induced
Exogenous hormone-induced headache Estro
A. Headache or migraine fulfilling criteria C and D A. He
B. Regular use of exogenous hormones B. Da
C. Headache or migraine develops or markedly worsens within
3 months of commencing exogenous hormones
C. He
D. Headache or migraine resolves or reverts to its previous pattern
within 3 months after total discontinuation of exogenous hormones
D. He3 months led to headache improvement in 92% of mi-
graine patients [44].
Migraine with aura The female dominance is also seen
in migraine with aura. In prevalence studies performed
after 1988 it reaches a prevalence of 1.2-3.7% in men and
2.6-10.8% in women [67]. In contrast to menstrual mi-
graine, migraine with aura occurs more frequently with
high estrogen levels [68]. Estrogen seems to change cortical
susceptibility and contributes to the development of cor-
tical spreading depression. The amplitude of the spreading
depression depends on the estrogen level [69]. The thresh-
old for cortical excitability and subsequent cortical spread-
ing depression is lowered through several genomic and
non-genomic mechanisms, including upregulation of
NMDA receptors, downregulation of GABA neurons and
modulation of axonal plasticity [4, 69, 70].
Exogenous hormone-induced headache In the West-
ern world, almost one third of women of reproductive
age use oral contraception [55]. The IHS identifies two
headache entities related to the use of hormonal contra-
ceptives: exogenous hormone-induced headache and
estrogen-withdrawal headache (Table 2).
Headache is one of the most common side effects of
hormonal therapies [71]. For instance Tamoxifen, men-
tioned above as a possible treatment for menstrual mi-
graine, can also cause headache. The onset of
hormone-induced headache is typically within the first
months of use [72]. Combined contraception remedies
(oral pill, transdermal patch, vaginal ring) appear to be
associated with both migraine and non-migraine head-
aches [73]. The effect in migraine patients is variable.
One out of two female migraine patients report no
change of the headache pattern, 15% experience an im-
provement, while 28% report worsening [74]. A negative
effect occurs more often in migraine with aura [72].
Headaches most frequently occur in the “pill-free” week
[53]. The neuronal nociceptive sensitivity is increased in
this week and the probability of getting a headache is
20% higher [74, 75]. Higher age (> 35 years) and a posi-
tive family history for migraine are risk factors [76, 77].
Possible contraceptive strategies to reduce headache in-
clude extended-cycle combined hormonal contraception,headache and estrogen-withdrawal headache
gen-withdrawal headache
adache or migraine fulfilling criteria C and D
ily use of exogenous estrogen for ≥3 weeks, which has been interrupted
adache or migraine develops within 5 days after last use of estrogen
adache or migraine resolves within 3 days of its onset
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mones like estradiol valerate/dienogest [17, 62, 78, 79].
Eliminating the pill-free week is associated with improve-
ment of headache, pelvic pain and quality of life [55].
In progestin-only methods (oral pill, subdermal im-
plant, depot-injection, levonorgestrel-releasing intrauter-
ine system) headache is a common complaint at the
beginning of therapy but classically improves after a few
months. There is no known association between
progestin-only methods and the worsening of migraine
[74]. On the contrary, frequency and intensity of mi-
graine can significantly improve with this type of contra-
ception. Ten percent of patients discontinue treatment
due to side effects, particularly spotting [80, 81].
Migraine with aura is associated with a twofold risk of
major cardiovascular events, like ischemic stroke. This
risk is directly proportional to aura frequency [55]. In
the meta-analysis of Schürks et al. a relative stroke risk
of 1.73 (95% CI 1.31-2.29) was found for any type of mi-
graine. The relative risk of stroke in women suffering
from migraine with aura is 2.08 (95% CI 1.3-3.31). The
relative risk of cardiovascular deaths in women with mi-
graine is 1.60 (95% CI 1.72-2.43) [82]. Older combined
hormonal therapies with high dosed estrogen (50–
150 μg) are associated with a 4.4-fold risk of stroke in
migraine patients, in particular in migraine with aura
and should not be used anymore. The modern
low-estrogen contraceptives (< 25 μg) seem much safer
[55, 56]. The 2017 consensus statement from the Euro-
pean Headache Federation and the European Society of
Contraception and Reproductive Health recommends
against the use of combined hormonal contraceptives in
women with migraine with aura seeking hormonal
contraception. They postulate a strong recommendation
to prefer non-hormonal (condoms, copper-bearing intra-
uterine device, permanent methods) or progestogen-only
alternatives. The same strategy is preferred in women
with migraine without aura who have additional cardio-
vascular risk factors, like smoking, arterial hypertension,
previous history of a trombo-embolic event. When there
are no such risk factors, combined hormonal contracep-
tives are considered a possible contraceptive option with
monitoring of migraine frequency and characteristics in
women without aura. Other medical conditions like
polycystic ovary syndrome or endometriosis can influ-
ence the risk/benefit profile and have an impact on the
preferred type of contraception [83].
Tension-type headache The impact of hormones on
TTH is less frequently studied. Like migraine, TTH oc-
curs more often in women than in men and some stud-
ies have suggested an increase during hormonal changes
such as menses or pregnancy. Menstruation can be an
aggravating factor in 40-60% of patients [13]. There isno evidence that TTH is influenced by hormonal contra-
ception [77].
Cluster headache The hypothalamus is thought to be
involved in CH pathophysiology based on its periodic
time locked occurrence. Sex hormones appear to modu-
late hypothalamic activity and could be effective as a
treatment for therapy refractory CH [84]. Both male and
female cluster patients show low testosterone levels and
testosterone supplementation could have a positive ef-
fect on headache attacks [2]. In the first studies from the
early 1990s, testosteron supplementation did not prove
effective, but more recent data show a good response in
a subgroup of cluster patients [84]. Clomifen is a select-
ive estrogen modulator, primarily used for ovulatory
stimulation in women. In men, it leads to an increase in
luteinizing and follicle stimulating hormones (LH, FSH)
and subsequently to higher testosterone levels. Further-
more, in animal model, it reduces prostaglandine pro-
duction [85]. In a case-series of 7 patients with chronic
cluster headache and 8 patients with episodic cluster
headache, Clomifen led to pain freedom after 15 days on
average [84].
Evidence of dysregulation of the hypothalamus-hypophysial
axis in trigeminal autonomic cephalgias could be derived
from a case with high nocturnal prolactin levels in a female
patient suffering from short, unilateral, neuralgiform head-
ache with conjunctival injection and tearing (SUNCT) [86].
Other headache types Pituitary diseases are often asso-
ciated with secondary headaches. Especially in female
patients with prolactinoma, migraine-like headaches or
worsening of a known migraine are reported. Mainly
mechanic aspects such as compression of pain sensitive
structures play a role in the development of headache,
but probably increased hormonal secretion has an im-
pact as well [87]. Prolactin is involved in regulation of
neuronal excitability and neurotransmission efficacy
[88]. Headache is commonly localized on the same side
of the tumor and gets better after treatment with dopa-
mine agonists [89, 90].
Perimenopause
Perimenopause is a period of decrease in reproductive
capability in middle-aged women. During this period the
growth and development of ovarian follicles stops and
the pattern of estrogen and progesterone production
changes. Signs of perimenopause include irregular men-
ses and periodic amenorrhea starting several years be-
fore menopause, also called the menopausal transition.
The average age of onset is 40 to 55 years and the aver-
age duration is 4 years, but in some women perimeno-
pause can last from several months up to 10 years [91].
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oped a classification for staging reproductive aging divid-
ing a women’s life into three stages based on the
menstrual cycle: premenopausal (or reproductive), peri-
menopausal (or menopausal transition) and menopausal
(or postmenopause) phase. There are two phases in the
menopausal transition: the early phase, characterized by
a variable cycle length (≥ 7 days), and a late amenorrhea
phase. Postmenopause can also be divided into two
stages. An early stage that lasts 5 to 8 years, characterized
by amenorrhea length more than 1 year, low estrogen
levels and high FSH level. The late stage is characterized
by stable low levels of ovarian hormones [92].
Perimenopause is characterized by fluctuations in both
estrogen and progesterone levels. Due to these constant
rapid changes in concentrations of ovarian hormones
60-70% of perimenopausal women experience symptoms
such as headaches, flushing, mood swings, depression,
decreased libido and sleep disturbance [91]. The de-
crease of estrogen in the late luteal phase leads to low
blood serum estrogen and progesterone levels and pro-
motes prostaglandins release by the uterus influencing
the menstrual cycle. This estrogen withdrawal becomes
more frequent and longer and can have a secondary im-
pact on headache patterns [46, 93].
Migraine Studies show that migraine prevalence in
menopause is lower compared to the perimenopausal
period. Menopausal transition seems to negatively im-
pact migraine frequency [94, 95]. As perimenopause and
menopause consist of several phases, each with a unique
hormonal pattern, they all have a different effect on mi-
graine. Another important factor is whether the meno-
pause is naturally or artificially induced and whether
HRT is used [92].
Fluctuation in the estrogen level is a known migraine
trigger. The hormonal alterations during perimenopause
can provoke migraine attacks in 50% of women with
menstrual migraine and menstrual related migraine. Ra-
ther stable levels of estrogen are replaced by a more
fluctuating pattern with periods of rapid decline in estro-
gen concentration, the so called estrogen withdrawal
[95–97]. The amount of estrogen withdrawal episodes is
correlated to headache attack frequency in women with
menstrual migraine in “early” perimenopause. Likewise
women can experience an increase in menstruation fre-
quency and in some cases an increase in vaginal bleed-
ing duration and severity [98]. This is related to an
increase in uterine prostaglandins, which also influences
central pain mechanisms and the trigeminovascular
system provoking menstrual migraine attacks [99, 100].
Another potential mechanism that can increase men-
strual migraine attack frequency is iron deficiency
caused by menstrual bleeding [101]. Depression, chronicpain syndrome and sleep disturbance can be other
symptoms related to perimenopause, which in turn can
lead to a secondary increase in migraine [102].
Women suffering from the premenstrual syndrome
were shown to experience more migraine attacks in late
perimenopause. The attack frequency declines in the
menopausal period. The premenstrual syndrome seems
a predictor of migraine attack frequency increase for
women entering menopause. These women are consid-
ered to have high sensitivity to hormonal fluctuations
and liability to moderately severe climacteric symptoms,
which in turn can have an impact on migraine [92].
Migraine and hormonal replacement therapy (HRT)
HRT is used to ease climax symptoms during meno-
pausal transition. It seems to have a significant influence
on migraine course. Studies confirm the correlation be-
tween the use of HRT, both oral and topical, and mi-
graine [103, 104]. Oral high dosed estrogen can provoke
new onset migraine with aura or worsening of
pre-existent migraine with aura. Nappi et al. concluded
that migraine deteriorated in women using oral estradiol
plus medroxyprogesterone acetate. The course of the
disease did not change with a transdermal patch [105].
A few years later MacGregor et al. showed that transder-
mal patches with estrogen can be effective in decreasing
migraine attack frequency in perimenopausal and post-
menopausal women, supposedly more effectively than
oral contraceptives [106]. Gels and patches based on es-
tradiol seem preferable over oral variants as constant
blood hormones levels are maintained stable. They
should be taken continuously without omission to pre-
vent rapid changes in estrogen blood levels, a known
trigger for migraine [105, 107]. These fluctuations in es-
trogen concentration have a more significant impact on
migraine than progesterone levels. Nand et al. studied
three groups of patients treated with different doses of
progesterone combined with estrogen and revealed that
changes in progesterone levels have no influence on mi-
graine course [92].
HRT containing low doses of natural estrogens are
linked to an insignificant risk of thromboembolism, in
contrast to the above mentioned combined oral contra-
ception. Nevertheless HRT should be stopped immedi-
ately in case of a new onset migraine with aura, a clear
increase in frequency or worsening of migraine with
aura, transitory ischemic attack or other vascular path-
ology [108].
Migraine and surgical menopause Natural menopause
seems to reduce migraine frequency, in contrast to sur-
gically induced menopause [5]. Neri et al. studied a
group of postmenopausal women [109]. Improvement of
migraine was seen in two thirds of cases compared to
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tion in days with TTH was observed. In women, who
underwent ovariectomy the course of migraine worsened
in the majority of women (67%). Thirtythree percent re-
ported migraine improvement. In women with natural
menopause 67% reported improvement in migraine
course, in 24% of patients no change was observed and
9% reported worsening [109]. There is still a debate on
possible migraine worsening in women who undergo
procedures such as hysterectomy, dilation and curettage
or cesarean section. Arumugam and Parthasarathy found
a positive correlation between these procedures and the
prevalence of migraine in women [110]. Oldenhave et al.
compared a group of 986 hysterectomized women and
5636 women without hysterectomy with one or both
ovaries preserved. The amount of days without migraine
in the group without hysterectomy was less compared to
the hysterectomy group. This data confirms the import-
ance of presence or absence of the uterus on migraine
frequency in menopausal women [92].
Tension-type headache The most common risk factors
for TTH are considered to be stress, fatigue and sleep
disturbance. During perimenopause these symptoms can
exacerbate and trigger TTH. But TTH also seems to
have a correlation with reproductive hormone levels
[111]. In some women menstruation can trigger TTH
and also pregnancy and menopause can influence the
course of TTH [93, 111]. In retrospective evaluations
38% to 46% of women reported an increase of headache
rate during menstruation [112, 113]. Arjona et al. even
tried to identify “menstrual TTH” and “menstrual re-
lated TTH” based on ICHD-2 criteria for pure menstrual
migraine and menstrually-related migraine. These terms
were not included into the ICHD [114]. Women in the
perimenopause reported their headaches to have new
characteristics and prevalence of TTH seems rather high
[115]. The prevalence of TTH in postmenopausal
women is reported to be higher than in premenopausal
women [116].
Cluster headache According to the literature the course
of CH in women is biphasic. The first peak of onset is
seen around the age of 20 and the second at age 50 to
60. The majority of female cluster patients experience
their first attack during menopause [116, 117]. The role
of estrogen in CH and the reason for CH onset in these
women remain unclear. Estrogen receptors are seen in
the trigeminal ganglion and in sensory neurons which
makes them susceptible to rapid changes in estrogen
level [118]. In menopause the reduced level of estrogen
is assumed to provoke CH, while the higher estrogen
level in the premenopausal phase can have a protective
effect [119]. However, based on the available literature,there is no clear evidence on the relationship between
CH and hormonal changes in women [120, 121].
In 2006 van Vliet et al. published a large retrospective
study in which data from more than 200 women with
CH were analyzed using questionnaires. Among women
with CH 9% reported more intense CH attacks during
menstruation, while frequency didn’t change. Eighty-six
percent of women were using lifelong oral contracep-
tives in this trial. Initiation of oral contraceptives was as-
sociated with an increase of days with headache in 12%
of participants. In 4% of the cases headache frequency
was reduced. Out of 111 pregnant women with episodic
CH 26 (23%) women reported “expected” CH attacks
not to occur. After childbirth 8 of them experienced CH
attacks in the first month. Nineteen patients (17%) had
attacks during pregnancy and 11 of them did not report
any changes in attack frequency or intensity [120].
Elderly
In the elderly, headache is less frequent compared to
younger patients. Headache disorders are mostly pri-
mary, but the relative frequency of secondary headache
is higher in the elderly [122]. In a random population
sample, the prevalence of headache in women and men
aged 55 to 74 years is approximately 66% and 53%, re-
spectively, compared to 92% and 74%, respectively, in
their younger counterparts between the ages of 21 to
34 years. The prevalence further declines in patients
aged over 75 to 55% for women and 22% in men [123].
In a population survey, the prevalence of frequent head-
ache in elderly women was 20% and 10% in elderly men
[124]. Another survey showed a 3-month prevalence of
headache among patients aged more than 66 years of
40.6% in men and 49.7% in women [125]. In summary,
all studies show that headache is more prevalent in
women compared to men at all ages, even among the
elderly. Hormonal factors take account for the
sex-specific difference in headache prevalence. However,
literature data about the relationship between headache
and hormonal activity in elderly women are scarce. Only
the relationship between migraine and estrogen has been
extensively studied in older women, possibly because of
the high prevalence of migraine and its sensitivity to
hormonal fluctuations.
Up to 51.9% of elderly patients referred for specialist
consultation report onset of headache after 65 years of
age [126]. Some primary headache disorders, and mostly
hypnic headache, have the tendency to start after the age
of 50, in contrast to most primary headache disorders,
which usually start at a younger age. However, migraine
still accounts for 0.5% of all new-onset headache disor-
ders after the age of 65 [127, 128]. The low estrogen
level in elderly women may explain why onset of mi-
graine in this age group is uncommon. Migraine with
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in younger age groups women outnumber men [129].
Migraine As mentioned above, the “estrogen withdrawal
hypothesis” attributes migraine episodes to the fluctu-
ation of estrogen levels throughout women’s reproduct-
ive events. After menopause, women’s serum levels of
estradiol drop. A lower frequency and severity of mi-
graine episodes is expected because of the stable low
serum levels of estrogen. Migraine prevalence declines
after menopause compared to the fertile period. How-
ever, the prevalence of migraine after the menopause is
still 10 to 29% across studies [5].
Interestingly, the decreased burden of migraine after
the menopause is more evident in population-based
studies when compared with those performed in head-
ache clinics or menopause clinics [94, 109, 115, 130–
134]. This can be explained by a possible selection bias
towards more severe forms of migraine in clinic-based
studies as compared to population-based studies [5].
Menopause has a different and variable effect on mi-
graine with or without aura [8]. In a population-based
study, the burden of migraine without aura decreased
after menopause while that of the variant with aura
remained stable [130]. In a headache clinic-based study
migraine without aura remained unchanged or even
worsened in the majority of patients possibly because of
the above mentioned selection bias of clinic-based stud-
ies [135]. Collectively, these data suggest that migraine
without aura improves more frequently after menopause
compared to migraine with aura. This can be a possible
consequence of migraine without aura being more sensi-
tive to female sex hormones [5]. However, the available
studies might have failed to show any change in the fre-
quency of migraine with aura after the menopause be-
cause of low statistical power [136]. When migraine with
aura does not subside with age, characteristics may
change, with increasing occurrence of aura without
headache. These auras constitute a difficult differential
diagnosis with transient ischemic attacks [137, 138]. An
aura is generated by cortical spreading depression while
migraine pain has been linked to the neurovascular sys-
tem. Elderly subjects may exhibit an intact cortical
spreading depression phenomenon, while the propensity
to neurovascular inflammation declines [139]. It is likely
that those changes can be a consequence of the post-
menopausal estrogen drop. However, to the best of our
knowledge, this has not been proven yet.
Together with female sex hormones, male sex hor-
mones might have an influence on the course of head-
ache disorders among elderly women. Only one
case-control study assessed the levels of androstenedione
and testosterone in the serum of postmenopausal
women with and without migraine and found nodifferences in the levels of these hormones when com-
paring women with and without migraine [140].
In conclusion, the postmenopausal drop of estrogen
might be beneficial for elderly women with migraine.
However, the proportion of women experiencing mi-
graine in menopause is still relevant.
Tension-type headache The effect of menopause on
TTH is less clear than the corresponding effect on mi-
graine. One population-based study addressing the topic
found that the frequency of TTH decreased less than
that of migraine after menopause. However, that same
study pointed out that fluctuations of sex hormone
levels during the life cycle might influence TTH as well
as migraine [131].
Hormonal therapy Hormonal manipulation in elderly
women cannot be considered for migraine prevention at
this time. HRT is contraindicated from 10 years after
menopause or in women aged 60 years or older due to
its potential cardiovascular side effects [141]. No other
hormonal therapy has been attempted in the prevention
of migraine in elderly women. Clomiphene citrate has
been used to treat chronic cluster headache and refrac-
tory primary SUNCT in single cases of elderly males
[142, 143]. Clomiphene has a direct effect on hypothal-
amic estrogen receptors and estrogen modulates hypo-
thalamic orexin expression. Hypothalamic estrogen
receptors co-localize to orexin neurons. Therefore,
clomiphene might upregulate orexin A levels, which in
turn inhibits the trigeminal nucleus caudalis activity and
secondarily suppresses the trigemino-autonomic reflex,
preventing hypothalamic-driven headache [142]. These
results are promising in considering hormonal therapies
as prevention for headache disorders in elderly women.
However, there are no studies to date.
Males
Migraine
Migraine is notoriously known to be two to three times
more prevalent in women than in men. Migraine is char-
acterized by its fluctuating nature, where periods of re-
mission are interspersed by relapse, with men more
likely to have longer periods of remission compared to
women. This female dominance of migraine suggests
that factors increasing female vulnerability and/or pro-
tecting males deserve greater focus in migraine patho-
physiology [144]. Interestingly, a study has shown that
male-to-female transsexuals who use antiandrogens to
suppress male sex characteristics and estrogens to in-
duce female sex characteristics have migraine rates simi-
lar to genetic females, further adding to the notion that
gender-specific hormones play a role in migraine preva-
lence. The authors suggest that this similarity in
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in the transsexual brain or that migraine headache is
part of the female gender role [145].
Animal models of migraine have attempted to investi-
gate the gender specific difference in migraine preva-
lence. In an animal model of familial hemiplegic
migraine type 1 (FHM1), it has been shown that orchiec-
tomy increases susceptibility to cortical spreading de-
pression, a response partially reversed with testosterone
replacement [146]. Also, female FHM1 mutant mice
were more susceptible to cortical spreading depression
than males [146–148].
Another explanation for increased prevalence of mi-
graine in women could be attributed to inherent differ-
ences in pain perception and processing. The
fundamental subjectivity of pain perception complicates
quantification of pain, yet it is generally accepted that
women and men experience pain differently due to both
biological and psychosocial traits [144]. Clinical studies
are often not designed to decipher gender-specific differ-
ence [149].
Cluster headache
In contrast to migraine, cluster headache has tradition-
ally been considered a male disease [150]. While the
characteristic physical attributes of cluster headache pa-
tients could point to high testosterone levels, the exact
opposite has been shown to be true [151]. Low testoster-
one levels in patients with episodic and chronic cluster
headaches were first noted in the 1970ies and later
reproduced [152–154]. Another study found low testos-
terone levels in the episodic but not chronic cluster
headache, a difference attributed by the authors to the
disruption of REM sleep [154].
The role of testosterone in cluster headache was fur-
ther studied by Stillman et al. in their investigation of la-
boratory findings of 7 male and 2 female patients with
treatment refractory cluster headache. Results of all 9
patients demonstrated low serum testosterone levels.
After supplementation with either pure testosterone in
the male patients or combination testosterone/estrogen
therapy in the female patients, pain freedom was
achieved for the first 24 h. Four male chronic cluster pa-
tients achieved headache remission. The authors con-
cluded that abnormal testosterone levels in patients with
episodic or chronic cluster headaches refractory to max-
imal medical management may be predictive of thera-
peutic response to testosterone replacement therapy [2].
Discussion
Reviewing recent literature, it becomes evident that most
experimental data on the causal relationship between sex
hormones and primary headaches covers women suffering
from migraine in the reproductive or perimenopausal phaseof their life. Particularly the effect of estrogen has been
studied and has been found to be of considerable value in
the pathogenesis of migraine. The estrogen withdrawal hy-
pothesis plays a central role here, but it is assumed that this
is only part of the mechanism. Some therapeutic strategies
have been developed based on this knowledge. Continuous
combined contraceptive therapy regimes can be considered
as a treatment for menstrual migraine. However, there is
currently no evidence to support the superiority of hormo-
nal therapy over non-hormonal pharmacological treatment
strategies. When using hormonal therapies in migraine pa-
tients, whether it is as a contraceptive or as a treatment, po-
tential cardiovascular risks should be considered when
deciding which type of hormones to use.
For the other primary headaches and more so ever for
headaches in male patients, the role of sex hormones is
vague. Is there more to know? It seems plausible that try-
ing to uncover the effects of sex hormones on the other
primary headaches may offer new insights in pathophysio-
logical mechanisms. The more we know on this matter,
the more targeted possible new therapies can be.
Conclusion
All three primary headaches, migraine, TTH, and CH,
occur in both genders, but with a sex-specific preva-
lence. Also, headache patterns display a temporal evolu-
tion that correlates to the hormonal shifts of a life cycle.
Collectively, these findings suggest that both male and
female sex hormones could play an important role in the
pathophysiology of primary headaches. Reviewing the
available literature on this matter, we can conclude that
especially the role of estrogen in female migraine pa-
tients has been well-studied. Detailed studies especially
in the elderly of both sexes, in CH, and TTH are war-
ranted in order to clearly elucidate the role of sex hor-
mones in not just migraine, but all primary headaches.
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